Wenhui Wang1, Xin Sun2, Zhouguang Hui3,4. 1. Department of Radiation Oncology, Peking Union Medical College Hospital, Chinese Academic of Medical Science and Peking Union Medical College, Beijing, China. 2. Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academic of Medical Science and Peking Union Medical College, Beijing, China. 3. Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academic of Medical Science and Peking Union Medical College, Beijing, China, drhuizg@163.com. 4. Department of VIP Medical Services, National Cancer Center/National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academic of Medical Science and Peking Union Medical College, Beijing, China, drhuizg@163.com.
Abstract
BACKGROUND: Brain metastasis is common in non-small-cell lung cancer (NSCLC) with driver gene mutations. Anaplastic lymphoma kinase (ALK) gene rearrangement is one of the common driver mutations in NSCLC. Tyrosine kinase inhibitor (TKI) has been the research hotspot at present. However, there are relatively few studies specified on the treatment of brain metastasis from ALK gene rearrangement NSCLC. The prognosis of these patients, the role of ALK-TKI, and the proper combination model of ALK-TKI with radiotherapy are worth further exploring. This review focuses on new data on the prognosis of ALK-TKI and the proper combination model of ALK-TKI with radiotherapy. SUMMARY: According to some retrospective trials, for ALKi-naïve ALK rearrangement NSCLC patients with brain metastasis, crizotinib together with radiotherapy seem to improve intracranial control rate, progression-free survival, and very likely improve overall survival; next-generation ALK-TKIs are now replacing crizotinib as first-line treatment. For patients with central nervous system progression during crizotinib application, combining radiotherapy could improve the local control rate while continuing crizotinib to control systemic disease. Second-/third-generation ALK inhibitors had higher intracranial ORR and DCR even after crizotinib-refractory situations, and they alone had a strong efficacy against intracranial tumors, in which situation radiotherapy might be omitted. Stereotactic radiosurgery (SRS) and whole-brain radiotherapy (WBRT) were both local treatment options for brain metastasis, and the preferred choice was hard to make. ALK resistance is complicated with a wide range of molecular changes, and future studies are needed to solve these problems. Anyway, further and larger prospective studied are worth exploring to offer a confirmed preferred choice of drugs and radiation. Key Messages: Next-generation ALK-TKIs are now replacing crizotinib as first-line treatment in ALKi-naïve ALK rearrangement NSCLC patients with brain metastasis, and they alone might have a strong efficacy against intracranial tumors in crizotinib-refractory situations in which occasion radiotherapy might be omitted. SRS and WBRT are both local treatment options for brain metastasis.
BACKGROUND:Brain metastasis is common in non-small-cell lung cancer (NSCLC) with driver gene mutations. Anaplastic lymphoma kinase (ALK) gene rearrangement is one of the common driver mutations in NSCLC. Tyrosine kinase inhibitor (TKI) has been the research hotspot at present. However, there are relatively few studies specified on the treatment of brain metastasis from ALK gene rearrangement NSCLC. The prognosis of these patients, the role of ALK-TKI, and the proper combination model of ALK-TKI with radiotherapy are worth further exploring. This review focuses on new data on the prognosis of ALK-TKI and the proper combination model of ALK-TKI with radiotherapy. SUMMARY: According to some retrospective trials, for ALKi-naïve ALK rearrangement NSCLCpatients with brain metastasis, crizotinib together with radiotherapy seem to improve intracranial control rate, progression-free survival, and very likely improve overall survival; next-generation ALK-TKIs are now replacing crizotinib as first-line treatment. For patients with central nervous system progression during crizotinib application, combining radiotherapy could improve the local control rate while continuing crizotinib to control systemic disease. Second-/third-generation ALK inhibitors had higher intracranial ORR and DCR even after crizotinib-refractory situations, and they alone had a strong efficacy against intracranial tumors, in which situation radiotherapy might be omitted. Stereotactic radiosurgery (SRS) and whole-brain radiotherapy (WBRT) were both local treatment options for brain metastasis, and the preferred choice was hard to make. ALK resistance is complicated with a wide range of molecular changes, and future studies are needed to solve these problems. Anyway, further and larger prospective studied are worth exploring to offer a confirmed preferred choice of drugs and radiation. Key Messages: Next-generation ALK-TKIs are now replacing crizotinib as first-line treatment in ALKi-naïve ALK rearrangement NSCLCpatients with brain metastasis, and they alone might have a strong efficacy against intracranial tumors in crizotinib-refractory situations in which occasion radiotherapy might be omitted. SRS and WBRT are both local treatment options for brain metastasis.
Authors: Hong Yuan; M Waleed Gaber; Kelli Boyd; Christy M Wilson; Mohammad F Kiani; Thomas E Merchant Journal: Int J Radiat Oncol Biol Phys Date: 2006-11-01 Impact factor: 7.038
Authors: E Shaw; C Scott; L Souhami; R Dinapoli; R Kline; J Loeffler; N Farnan Journal: Int J Radiat Oncol Biol Phys Date: 2000-05-01 Impact factor: 7.038
Authors: Andrew J Weickhardt; Benjamin Scheier; Joseph Malachy Burke; Gregory Gan; Xian Lu; Paul A Bunn; Dara L Aisner; Laurie E Gaspar; Brian D Kavanagh; Robert C Doebele; D Ross Camidge Journal: J Thorac Oncol Date: 2012-12 Impact factor: 15.609
Authors: Eric L Chang; Jeffrey S Wefel; Kenneth R Hess; Pamela K Allen; Frederick F Lang; David G Kornguth; Rebecca B Arbuckle; J Michael Swint; Almon S Shiu; Moshe H Maor; Christina A Meyers Journal: Lancet Oncol Date: 2009-10-02 Impact factor: 41.316
Authors: Paul W Sperduto; T Jonathan Yang; Kathryn Beal; Hubert Pan; Paul D Brown; Ananta Bangdiwala; Ryan Shanley; Norman Yeh; Laurie E Gaspar; Steve Braunstein; Penny Sneed; John Boyle; John P Kirkpatrick; Kimberley S Mak; Helen A Shih; Alex Engelman; David Roberge; Nils D Arvold; Brian Alexander; Mark M Awad; Joseph Contessa; Veronica Chiang; John Hardie; Daniel Ma; Emil Lou; William Sperduto; Minesh P Mehta Journal: JAMA Oncol Date: 2017-06-01 Impact factor: 31.777
Authors: Ying Dai; Quanxiang Wei; Christian Schwager; Janina Hanne; Cheng Zhou; Klaus Herfarth; Stefan Rieken; Kenneth E Lipson; Jürgen Debus; Amir Abdollahi Journal: Radiat Oncol Date: 2018-01-05 Impact factor: 3.481
Authors: Paola Anna Jablonska; Joaquim Bosch-Barrera; Diego Serrano; Manuel Valiente; Alfonso Calvo; Javier Aristu Journal: Cancers (Basel) Date: 2021-04-29 Impact factor: 6.639
Authors: Nikolaj Frost; Petros Christopoulos; Diego Kauffmann-Guerrero; Jan Stratmann; Richard Riedel; Monica Schaefer; Jürgen Alt; Sylvia Gütz; Daniel C Christoph; Eckart Laack; Martin Faehling; Richard Fischer; Klaus Fenchel; Sebastian Haen; Lukas Heukamp; Christian Schulz; Frank Griesinger Journal: Ther Adv Med Oncol Date: 2021-02-09 Impact factor: 8.168
Authors: Arlou Kristina Angeles; Petros Christopoulos; Zhao Yuan; Simone Bauer; Florian Janke; Simon John Ogrodnik; Martin Reck; Matthias Schlesner; Michael Meister; Marc A Schneider; Steffen Dietz; Albrecht Stenzinger; Michael Thomas; Holger Sültmann Journal: NPJ Precis Oncol Date: 2021-12-07